Key things
Most vitiligo treatments need at least 3–4 months before they deserve any serious verdict. NB-UVB and ruxolitinib cream have the strongest evidence for slow but meaningful improvement over longer timelines. Tacrolimus often shows its best results in the 3–6 month range, especially on the face. Systemic therapies are judged less by repigmentation and more by whether they stop active disease early.
- 3 months Usually too early to quit most topicals, NB-UVB, or ruxolitinib cream.
- 6 months The first serious checkpoint for most treatments.
- 9 months If there is still zero signal, it is time for a more honest conversation.
Repigmentation is slow, gradual, and highly individual, but persistence (with professional guidance) often pays off.
What is a normal response time?
Most vitiligo therapies need at least 3–4 months before they deserve any serious verdict. Early changes can show up sooner on the face and neck, which usually respond best. Hands, feet, fingertips, and areas with white hairs are the classic slowpokes. So “nothing happened by month 3” means one thing on the cheek and something quite different on a knuckle.
Also, response is not always the same as repigmentation. Some treatments are meant to stop the disease first and recolor the skin second. That distinction saves a lot of unnecessary despair.
Topical treatments
This group includes topical steroids, calcineurin inhibitors such as tacrolimus or pimecrolimus, and JAK inhibitors such as ruxolitinib cream.
Classic topicals: steroids and calcineurin inhibitors
For tacrolimus, expert consensus places peak repigmentation response in the 3–6 month window, with the face showing the best outcomes and palms, soles, and fingertips showing the weakest. A meta-analysis found that 55% of patients had at least modest repigmentation after a median of 3 months of tacrolimus monotherapy. Some researchers argue that >80% of patients with no or limited repigmentation at 6 months who continued to apply ruxolitinib cream over an additional 18 months achieved significant improvements.
In plain English: if there is no sign at all after 3 months of a topical, do not panic yet. If there is still absolutely nothing by 6 months, that is a proper checkpoint. If classic topical monotherapy has produced zero signal by 9 months, especially outside hard-to-treat sites, it is reasonable to question whether this is the right plan.
Ruxolitinib cream: the exception that keeps going
Ruxolitinib cream behaves a bit differently. In the phase 3 TRuE-V program, facial response rates kept improving with time: about 18% reached F-VASI75 by week 24, about 31% by week 52, and about 66% by week 104 among those treated from day 1. That makes it the clearest modern example of a therapy where month 6 is not the end of the story.
So while 6 months is still an important checkpoint, ruxolitinib is the main exception to the usual “if nothing by 9 months, rethink” logic. Meaningful gains can continue well past a year.
Systemic treatments
Systemic therapy is different. Oral mini-pulse steroids and similar approaches are mainly used for active, spreading vitiligo. Their first job is to stop the fire, not repaint the wall.
That is why the early checkpoint here is not “Do I see freckles of pigment yet?” but “Has the disease stopped spreading?” In one prospective study of oral mini-pulse prednisolone, 88% of patients achieved arrest of disease activity, with mean time to stability around 4.41 months.
So for systemic treatment, if the disease is still clearly active after about 3 months, reassessment makes sense. At 6 months, lack of stabilization is a stronger warning sign than lack of visible repigmentation. Late color return may still happen, especially if topicals or UVB are added, but that is not the main job of systemic therapy.
NB-UVB phototherapy
If one treatment category deserves the phrase “don’t give up too soon,” it is NB-UVB.
Evidence consistently shows that NB-UVB needs time. At least 6 months are usually needed to judge responsiveness, and about a year may be needed for maximal results. A retrospective cohort of 579 patients identified a very-slow responder group that showed no response during the first 48 sessions, yet later achieved measurable repigmentation by 96 sessions.
That means 3 months is often far too early to label NB-UVB a failure. Six months is the first serious checkpoint. Nine months is where the conversation becomes more honest: if adherence has been good, dosing has been adequate, and there is still absolutely no signal, then it may be time to rethink or add combination treatment.
What makes UVB so tricky?
UVB phototherapy often produces slow, cumulative gains rather than a dramatic early payoff. That is why people quit too soon. They do a few months, see nothing theatrical, get discouraged, and walk away just before the biology finally starts cooperating. Vitiligo, sadly, is not known for rewarding impatience.
A better 3/6/9-month rule
| Timeline | What it usually means | Practical takeaway |
|---|---|---|
| 3 months | Usually too early to quit NB-UVB or ruxolitinib cream. Topicals may or may not have shown a signal yet, especially outside the face. For systemic therapy, the main question is whether the spread has slowed or stopped. | Recheck adherence, body site, and expectations. Do not panic yet. |
| 6 months | This is the first real checkpoint for most treatments. If there is still no visible or photographic signal at all, it is time to review adherence, diagnosis, and whether combination treatment makes more sense. | Have an honest review with your dermatologist. Photos help. |
| 9 months | If classic topical therapy or UVB still shows zero progress despite proper use, a pivot is reasonable. With ruxolitinib cream, later improvement remains plausible, so the decision is less straightforward. | Do not confuse patience with denial. Sometimes the answer is “stay the course.” Sometimes the answer is “new plan.” |
Why the same timeline does not fit everyone
Response depends on location, disease duration, disease stability, adherence, and individual biology. The face and neck are the overachievers. Hands and feet are the bureaucrats of the disease: slow, stubborn, and unimpressed by your schedule. Newer, stable patches usually do better than long-standing or actively spreading ones. And yes, consistent treatment matters more than people like to hear.
Bottom line
Late responders in vitiligo are real. But they are not evenly distributed across treatments.
NB-UVB and ruxolitinib cream have the strongest case for slow-but-real improvement over longer timelines. Tacrolimus often peaks in the 3–6 month range, especially on the face. Systemic therapy is judged less by late repigmentation and more by whether it stabilizes active disease early.
So yes, do not quit too soon.
But also: do not keep a dead regimen on life support just because hope is free.